Company Profile
Immuron Stock Price, News & Analysis
- Ticker:
- IMRN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Australia and listed in the U
Stock performance
1.10 USD (0.00%)
Close
Last updated: August 6, 2026
10.8M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, IMRN was little changed and closed at $1.10. No new same-company headline was identified in the current news window.
Company overview
Business overview
Immuron is a biotechnology company focused on orally delivered immunotherapies and gastrointestinal health. Its business is centered on leveraging immune biology for GI and infectious-related uses.
Geographic Base and Sector Classification
Immuron is headquartered in Australia and listed in the U.S. market. It sits in small-cap biotechnology with a GI and immunology focus.
Business Model Characteristics
The company depends on clinical and commercial progress, plus capital efficiency. Investors usually watch data, product uptake, and strategic development.
Position Within the Biotechnology Landscape
Immuron occupies a niche GI-immunology position within biotech. The stock is sensitive to whether oral immune biology can translate into a meaningful market.
Future catalysts
Immuron’s catalysts are its oral immunotherapy and infectious-disease products, plus any commercialization update that shows the platform can keep gaining traction. The company moves on recurring demand and product execution.
Recent news
- 01
- 02
- 03
- 04
Immuron Double Digit 3Q Sales Growth
Source: Immuron
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Immuron (IMRN)?
Immuron (IMRN) most recently closed at 1.10 USD, a 0.00% move versus the previous session.
What is the market cap of Immuron (IMRN)?
Immuron currently has a market capitalization of 10.8M USD on BioPharmSignal.
What does Immuron do?
Immuron is a biotechnology company focused on orally delivered immunotherapies and gastrointestinal health. Its business is centered on leveraging immune biology for GI and infectious-related uses.
On which exchange is IMRN stock listed?
Immuron (IMRN) is associated with NASDAQ, Australia and listed in the U, Biopharma.
What is Immuron?
Immuron’s catalysts are its oral immunotherapy and infectious-disease products, plus any commercialization update that shows the platform can keep gaining traction.
Which conditions is Immuron targeting with Immuron?
Immuron’s catalysts are its oral immunotherapy and infectious-disease products, plus any commercialization update that shows the platform can keep gaining traction.
How does Immuron describe recent progress with Immuron?
Immuron’s catalysts are its oral immunotherapy and infectious-disease products, plus any commercialization update that shows the platform can keep gaining traction.
What future catalysts are investors watching for Immuron?
Immuron’s catalysts are its oral immunotherapy and infectious-disease products, plus any commercialization update that shows the platform can keep gaining traction. The company moves on recurring demand and product execution.